SC-43 + cisplatin

**SC-43 + cisplatin** is an experimental combination therapy investigated primarily for cancer treatment. **SC-43** is a small molecule that inhibits tumor growth by activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and inhibition of phosphorylated STAT3 (p-STAT3) signaling, thereby repressing oncogenic pathways. **Cisplatin** is a platinum-based chemotherapy drug that exerts cytotoxic activity by binding DNA, causing crosslinking and inducing apoptosis. The combination aims to leverage the antineoplastic effects of both drugs, enhance therapeutic efficacy, and overcome resistance mechanisms, particularly in platinum-sensitive and -resistant cancers such as lung, ovarian, and cervical cancer[1][4].